Inhibitex has announced
that the FDA has granted Aurexis, its humanized monoclonal antibody, fast
track designation. Aurexis is being evaluated in a Phase II clinical trial
for the first-line treatment of serious hospital-associated Staphylococcus
aureus bloodstream infections.
Favrille has initiated
a Phase III clinical trial (FavId-06) evaluating the company’s lead product
candidate, FavId. FavId, an active immunotherapy, is being studied as a potential
therapy for the treatment of follicular B-cell non-Hodgkin’s lymphoma.
Cardiome Pharma Corp.
has initiated subject dosing in its Phase I study of a controlled release
formulation of oral RSD1235, which is being developed as a chronic treatment
for atrial fibrillation.